J&J sues Amgen over cancer drug sales tactics

10/14/2005 | NYTimes.com

Johnson & Johnson filed an antitrust suit alleging Amgen used sales tactics to force cancer clinics to buy its Aranesp rather than J&J's Procrit, drugs used to treat chemotherapy-related anemia. The suit notes U.S. sales of the two drugs are expected to reach $2.8 billion this year. An Amgen spokeswoman said, "We believe the allegations are not legitimate and we intend to fight this."

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA